Search results
1 Beaten-Down S&P 500 Dividend Stock to Buy in June and Hold For a Decade or Longer
Motley Fool via Yahoo Finance· 6 minutes agoThe Stock Advisor service has more than quadrupled the return...Motley Fool has positions in and...
RBC Capital lifts Moderna shares target, highlights RSV vaccine approval By Investing.com
Investing.com· 22 hours agoThe revision follows the approval of Moderna's Respiratory Syncytial Virus (RSV) vaccine by...
Moderna Investors Just Got Some Bullish News
Motley Fool via Yahoo Finance· 1 day agoSo, even if Moderna shares don't take off overnight, the RSV approval is bullish news for shareholders -- and a great reason...provides investors with an...
Is Moderna Stock a Buy Now That It's a 2-Product Company?
Motley Fool via Yahoo Finance· 23 hours agoOn March 31, it had $12.2 billion in cash and investments, or...year earlier. I don't expect much...
ASCO: After Keytruda, Merck builds 3-pronged cancer strategy starring Moderna-partnered vaccine
FierceBiotech· 22 hours agoAs Keytruda’s 2028 patent cliff looms large, Merck & Co.’s renewed R&D oncology strategy focuses on...
FDA approves Moderna’s mRNA RSV vaccine
The Hill via Yahoo News· 4 days agoThe Food and Drug Administration (FDA) has approved Moderna’s RSV mRNA vaccine for adults older than 60 years. The approval makes RSV the second disease...
Moderna just got FDA approval for its RSV vaccine — only its second product on the market
Quartz· 4 days agoThe Food and Drug Administration on Friday approved Moderna’s mRNA-based respiratory syncytial virus...
Moderna’s vaccine for RSV gets FDA approval for people 60 and older - The Boston Globe
The Boston Globe· 4 days agoModerna said Friday that US drug regulators have approved its second product, a vaccine for...
Why Moderna Stock Is Sinking This Week
Motley Fool via Yahoo Finance· 5 days agoShould you invest $1,000 in Moderna right now? Before you buy stock in Moderna, consider this: The Motley Fool...Advisor provides investors with an...
COVID shots should target JN.1, KP.2 subvariants in 2024-25 campaign, US FDA staff says
Reuters· 20 hours agoVaccine makers should consider targeting one of the currently dominant JN.1 variants and...